GlassScriptPhysician profile
Jennifer L Even
NPI 1104827468
$1,459.09
in general payments reported to CMS, 2019-2025
29 companies · $341 in 2025
The $341 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $133 · 2020: $83.77 · 2021: $125 · 2022: $511 · 2023: $167 · 2024: $98.70 · 2025: $341.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $532 · Education: $74.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $531.65 |
| Education | $74.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tandem Diabetes Care, INC. | $248.66 | 2022 | |
| Medtronic, INC. | $190.19 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $157.71 | 2025 | Airsupra |
| Astellas Pharma US INC | $123.64 | 2021-2023 | Veozah |
| Abbvie INC. | $114.27 | 2019-2022 | |
| Sumitomo Pharma America, INC. | $75.13 | 2023-2024 | Myfembree |
| Novo Nordisk INC | $60.16 | 2024-2025 | Ozempic, Rybelsus, Wegovy |
| Therapeuticsmd, INC. | $55.14 | 2019-2021 | |
| Aimmune Therapeutics, INC. | $42.00 | 2024-2025 | Zenpep |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $37.94 | 2024-2025 | Caplyta |
| Coloplast Corp | $33.07 | 2022 | |
| Hologic Sales and Service, LLC | $22.21 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $22.10 | 2025 | Rexulti |
| Covidien LP | $22.03 | 2019 | |
| Grifols USA, LLC | $21.42 | 2025 | Prolastin-C Liquid |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exeltis, USA INC. | $19.96 | 2023 | Slynd |
| Pfizer INC. | $19.89 | 2025 | |
| Masimo Corporation | $19.65 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $19.28 | 2019 | |
| Pacira Pharmaceuticals Incorporated | $18.67 | 2021 | |
| Xeris Pharmaceuticals, INC. | $18.60 | 2025 | Gvoke Hypopen |
| Coopersurgical, INC. | $17.74 | 2019 | |
| Cleerly, INC. | $16.82 | 2024 | Cleerly Labs, Cleerly Ischemia |
| Axsome Therapeutics, INC. | $15.91 | 2025 | Auvelity |
| Avion Pharmaceuticals | $15.18 | 2021 | |
| Ascend Therapeutics US, LLC | $14.52 | 2021 | |
| Amgen INC. | $13.74 | 2020 | |
| Evofem Biosciences, INC. | $11.81 | 2021 | |
| Sanofi Pasteur INC. | $11.65 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jennifer Even listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.